Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 131Gastrointestinal Stromal Tumors 67Leukemia 66Leukemia, Myeloid, Chronic-Phase 47Precursor Cell Lymphoblastic Leukemia-Lymphoma 41Blast Crisis 22Brain Neoplasms 15Philadelphia Chromosome 14Melanoma 13Sarcoma 12Neoplasms 12Neoplasm Metastasis 12Leukemia, Myeloid, Acute 12Leukemia, Myeloid, Accelerated Phase 12Glioblastoma 12Lung Neoplasms 11Prostatic Neoplasms 10Leukemia, Myeloid 9Gliosarcoma 9Glioma 8Breast Neoplasms 8Primary Myelofibrosis 7Leukemia, Myelomonocytic, Chronic 7Central Nervous System Neoplasms 7Astrocytoma 7Recurrence 6Polycythemia Vera 6Ovarian Neoplasms 6Oligodendroglioma 6Myeloproliferative Disorders 6

Interventions

vandetanib 12cabozantinib 8selpercatinib 5Sorafenib 5Everolimus 5Magnetic Resonance Spectroscopy 3Capecitabine 3sargramostim 2pralsetinib 2lutetium Lu 177 dotatate 2lenvatinib 2Trastuzumab 2Temozolomide 2Sunitinib 2Specimen Handling 2Octreotide 2High-Energy Shock Waves 2Gefitinib 2Doxorubicin 2yeast-CEA vaccine 1veliparib 1vatalanib 1tumor necrosis factor-alpha, CNGRC fusion protein, human 1tipifarnib 1temsirolimus 1tanespimycin 1sacubitril and valsartan sodium hydrate drug combination 1rovalpituzumab tesirine 1ponatinib 1pentetreotide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Medullary × Imatinib Mesylate × Clear all
NCT00354523 2014-12-17

Imatinib in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma

M.D. Anderson Cancer Center

Phase 1/2 Terminated
21 enrolled
Head & Neck

Thyroid Neoplasms, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡